ClinicalTrials.gg
CompletedNCT01769235Updated May 5, 2017

Study Comparing Clindamycin Phosphate and Benzoyl Peroxide Gel to Acanya® Gel and Both to a Vehicle Control in the Treatment of Acne Vulgaris

A Phase 1 interventional study of Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% and Acanya® Gel, 1.2%/2.5% in Acne Vulgaris, sponsored by Taro Pharmaceuticals USA. Completed. Open to participants aged 12 Years to 40 Years. Per ClinicalTrials.gov, last updated 2017-05-05.

Sponsored by Taro Pharmaceuticals USA (part of Sun Pharmaceutical Industries Limited) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
1,215
Allocation
Randomized
Ages
12 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Acne Vulgaris by Sun Pharmaceutical Industries Limited — none open to participants now, 1 under way, none of them phase 3. Acne Vulgaris · Sun Pharmaceutical Industries Limited.

Enrollment
3rd of 30
1,215 · median 727
Started
2012
with 2 others
Phase 1
21 of 30
none open now
Registered
4th of 30
by date

Among the 30 studies in Acne Vulgaris by Sun Pharmaceutical Industries Limited, this one is the 3rd largest by enrollment, is one of 3 that started in 2012, is one of 21 in phase 1, and was the 4th registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

None of the 30 studies in Acne Vulgaris by Sun Pharmaceutical Industries Limited is open now. The open studies under Acne Vulgaris, anywhere →

Where they have run

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 12 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 30 studies in Acne Vulgaris by Sun Pharmaceutical Industries Limited as a file.
02

Study summary

The objective of this study is to compare the safety and efficacy profiles of Taro Pharmaceutical Inc.'s Clindamycin Phosphate and Benzoyl Peroxide Gel 1.2%/2.5% to Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% and to demonstrate the superior efficacy of the two active formulations over that of the vehicle in the treatment of acne vulgaris.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

Keywords

  • Acne Vulgaris
  • Clindamycin Phosphate and Benzoyl Peroxide Gel
  • Acanya® Gel
04

Who can participate

Ages eligible
12 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be willing and able to provide written /assent for the study.
  • Be 12 to 40 years of age, inclusive. A subject may be of either sex and any race/ethnicity.
  • Have a clinical diagnosis of facial acne vulgaris with 25 or greater non-inflammatory lesions and 20 or greater inflammatory lesions and no more than 2 nodulocystic lesions.
  • Have a baseline Investigator's Global Assessment of acne severity grade of 2, 3 or 4 on a severity scale of 0 to 4.
  • Be willing and able to understand and comply with the requirements of the study, apply the study medication as instructed, refrain from use of all other topical acne medication and topical antibiotics during the 12-week treatment period, return for the required treatment period visits, comply with therapy prohibitions, and able to complete the study.
  • Be in general good health and free from any disease, other than acne vulgaris, that might interfere with the study evaluations.
  • Female subjects of must have a negative urine pregnancy test amd must be willing to use a medically accepted method of during the study.

Exclusion criteria

Exclusion Criteria:

  • Presence of more than 2 facial nodulocystic lesions (i.e., nodules and cysts).
  • Current diagnosis of acne conglobata, acne fulminans, or secondary acne.
  • Presence of active cystic acne, or polycystic ovarian syndrome.
  • History or presence of Crohn's disease, ulcerative colitis, regional enteritis, or antibiotic-associated colitis.
  • Presence of any other facial skin condition that might interfere with acne vulgaris diagnosis and/or assessment.
  • Excessive facial hair that would interfere with diagnosis or assessment of acne vulgaris.
  • History of unresponsiveness to topical clindamycin phosphate and/or benzoyl peroxide therapy.
  • Start or change of dose of estrogens or hormonal treatment 3 months prior to baseline or throughout the study.
  • Use of medicated make-up throughout the study and significant change in the use of consumer products within 30 days of study entry and throughout the study.
  • Use of any of the following treatments more recently than the indicated prior to visit 1/day 1; need or intent to continue to use any of the following treatments during the study: oral retinoids or therapeutic Vitamin A supplements of greater than 10,000 units/day; systemic ; systemic antibiotics; systemic treatment for acne vulgaris ; systemic anti-inflammatory or agents (NSAID use is allowed on an as-needed basis but for no more than 7 days of consecutive use, low dose aspirin is allowed if on a stable dose for at least 30 days); Spironolactone; use on the face of cryodestruction or chemodestruction, dermabrasion, photodynamic therapy, acne surgery, intralesional steroids, x-ray therapy; topical retinoids; topical steroids; topical anti-acne medications; topical anti-inflammatory agents; topical antibiotics; medicated cleansers; use of tanning booths, sun lamps, sunbathing or excessive exposure to the sun; antipruritics, including antihistamines.
  • History of or allergy to clindamycin phosphate, benzoyl peroxide, and /or any ingredient in the study medication.
  • Females who are pregnant, breastfeeding, intending to become pregnant during the study, or who do not agree to use an acceptable form of during the study.
  • Consumption of excessive alcohol, abuse of drugs, or a condition that could compromise the subject's ability to comply with study requirements.
  • Any condition or situation other than acne vulgaris that would interfere with the study evaluations or optimal participation.
  • Use of any drugs within 30 days prior to visit 1/day 1.
  • Participation in any other clinical study in the 30 days prior to signing the form.
  • Previous participation in this study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,215 participants (actual)

Study arms

  • Experimental
    Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%

    Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% (Taro Pharmaceuticals Inc.)

    Drug: Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%

  • Active comparator
    Acanya® Gel, 1.2%/2.5%

    Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% (Dow Pharmaceutical Sciences, Inc., marketed by Valeant Pharmaceuticals North America LLC)

    Drug: Acanya® Gel, 1.2%/2.5%

  • Placebo comparator
    Vehicle of test product

    Vehicle of test product (Taro Pharmaceuticals Inc.)

    Drug: Vehicle of test product

Interventions

  • DrugClindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%

    Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% (Taro Pharmaceuticals Inc.)applied at approximately the same time once daily for 84 days (12 weeks).

  • DrugAcanya® Gel, 1.2%/2.5%

    Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% (Dow Pharmaceutical Sciences, Inc., marketed by Valeant Pharmaceuticals North America LLC)applied at approximately the same time once daily for 84 days (12 weeks).

  • DrugVehicle of test product

    Vehicle of test product (Taro Pharmaceuticals Inc.)applied at approximately the same time once daily for 84 days (12 weeks).

06

What researchers measure

Primary outcomes

  1. Mean percent change in inflammatory lesion counts.

    Mean percent change from baseline to week 12 in the inflammatory (papules and pustules) lesion counts.

    Time frame: 12 weeks

  2. Mean percent change in non-inflammatory lesion counts.

    Mean percent change from baseline to week 12 in the non-inflammatory (open and closed comedones) lesion counts.

    Time frame: 12 weeks

Secondary outcomes

  1. Clinical response of "success".

    The proportion of subjects at week 12 with a clinical response of "success" is defined as an Investigators Global Assessment score that is at least 2 grades less than the baseline assessment.

    Time frame: 12 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2012, a primary completion of Sep 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2013
First posted
Jan 16, 2013
Start
Nov 2012
Primary completionActual
Sep 2013
CompletionActual
Dec 2013
Last update
May 5, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01769235
Responsible party
Sponsor
First posted
Jan 16, 2013
Start date
Nov 2012
Primary completion
Sep 2013
Completion
Dec 2013
Last update
May 5, 2017

Study contacts

Symbio CRO
study chair · http://symbioresearch.com/

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion